LEADER 04114nam 22005055 450 001 9910847091803321 005 20240329053032.0 010 $a3-031-51757-1 024 7 $a10.1007/978-3-031-51757-0 035 $a(CKB)31253183400041 035 $a(MiAaPQ)EBC31266974 035 $a(Au-PeEL)EBL31266974 035 $a(MiAaPQ)EBC31233406 035 $a(Au-PeEL)EBL31233406 035 $a(DE-He213)978-3-031-51757-0 035 $a(EXLCZ)9931253183400041 100 $a20240327d2024 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCardiac Amyloidosis $eDiagnosis and Treatment /$fedited by Michele Emdin, Giuseppe Vergaro, Alberto Aimo, Marianna Fontana 205 $a1st ed. 2024. 210 1$aCham :$cSpringer Nature Switzerland :$cImprint: Springer,$d2024. 215 $a1 online resource (319 pages) 311 $a3-031-51756-3 327 $a1. Tribute to Claudio Rapezzi -- 2. Giampaolo Merlini and the Pavia School -- 3. A brief history of amyloidosis -- 4. Pathophysiology, classification and epidemiology of amyloidosis -- 5. Amyloid light chain (AL) amyloidosis -- 6. Hereditary transthyretin amyloidosis -- 7. Wild-type ATTR amyloidosis -- 8. Electrocardiographic patterns -- 9. Echocardiography: a gatekeeper to diagnosis -- 10. Cardiovascular magnetic resonance: characterization of myocardial involvement -- 11. Biomarkers: monoclonal protein and indicators of cardiac damage -- 12. Plasma transthyretin and its ligands -- 13. Cardiac Scintigraphy with Bone-Avid Tracers ? Old and New Applications -- 14. PET-CT: a tool for etiological diagnosis -- 15. The role of tissue biopsy: identification of the amyloid precursor and beyond -- 16. From red flags to diagnosis -- 17. Risk prediction and follow-up -- 18. Differential diagnoses in clinical mimics -- 19. Applications of Artificial Intelligence in Amyloidosis -- 20. Treatment of amyloid light-chain amyloidosis -- 21. Treatment of ATTR amyloidosis: from stabilizers to gene-editing -- 22. Treatment of cardiac complications -- 23. Monitoring disease progression and response to disease-modifying treatments -- 24. Cardiac amyloidosis: open issues and future perspectives. 330 $aCardiac amyloidosis (CA) is caused by the accumulation of amyloid fibrils in the extracellular space of the myocardium, with clinical manifestations including conduction disturbances and heart failure. CA has traditionally been considered a rare disease, lacking effective therapies and with a poor prognosis, but in recent years, increased possibilities for non-invasive diagnosis and greater awareness of the disease have led to the identification of a growing number of cases, challenging the concept of CA as a rare disease. This is why the ability to recognise and manage patients with CA should become part of the core curriculum of cardiologists, but also of internal medicine specialists, neurologists, nephrologists, haematologists, and general practitioners. This book, written by leading experts in the field, will provide the state-of-the-art in the diagnosis and management of CA and will also discuss the latest research developments and future research directions. The volume appears to be a timely one, given the great interest of clinicians and researchers in CA and the exponential increase in publications in recent year, and will be of interest to cardiologists, internal medicine and other disciplines specialists who may encounter patients with CA in their clinical practice, as well as general practitioners. 606 $aMedical sciences 606 $aHealth Sciences 615 0$aMedical sciences. 615 14$aHealth Sciences. 676 $a616.3995 700 $aEmdin$b Michele$01735829 701 $aVergaro$b Giuseppe$01735830 701 $aAimo$b Alberto$01735831 701 $aFontana$b Marianna$01735832 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910847091803321 996 $aCardiac Amyloidosis$94155251 997 $aUNINA